DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1473)

Venous Thromboembolism | Landscape & Forecast | Disease Landscape & Forecast

Venous Thromboembolism | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Venous thromboembolism ( VTE ), comprising deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ), represents a significant public health and financial burden. The launch of novel oral anticoagulants ( NOAC s) for VTE is addressing the need for more-convenient alternatives compared with long-established therapies, and these agents will drive market growth in the near to mid term. Toward the end of our forecast period, generic NOAC s will be widely available, and the VTE market will enter a new phase of evolution. There are still considerable areas of unmet need within VTE , such as the primary prophylaxis of VTE in acute medically ill patients and ambulatory cancer patients. The ongoing label expansion program for the NOAC s and emerging therapies such as betrixaban and IONIS-FXIRx offer potential solutions to these unmet needs.
Questions Answered:

Which patient subgroups will have maximum impact on global VTE sales? What will be the key drivers and deterrents of VTE therapy uptake during the 2016-2026 forecast?
How do thought leaders perceive each anticoagulant therapy? How will uptake of the newer agents in the market affect current market-leading therapies? Which agents will be most successful and why?
What do thought leaders think of the label expansion programs for the NOAC s? What do physicians think of emerging therapies such as betrixaban and IONIS-FXIRx?
Which patient subpopulations have the greatest remaining unmet need and commercial potential? Which drugs currently under development will fulfill these unmet needs?

Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with thought leaders in the field.
Epidemiology: Number of DVT events; number of PE events; number of hospitalization events (orthopedic surgery, major non-orthopedic surgery, nonsurgical) eligible for VTE acute primary prophylaxis; number of prevalent cases of cancer patients eligible for VTE primary prophylaxis.
Population segments in market forecast: Primary prophylaxis indications (major orthopedic surgery, non-orthopedic surgery, nonsurgical patients, cancer patients eligible for prophylaxis); acute DVT treatment and secondary prophylaxis; acute PE treatment and secondary prophylaxis.
Emerging therapies: Phase II: 2 drugs; Phase III: 5 drugs; preregistered: 1 drug. Coverage of select preclinical and Phase I products.

  • Pub Date: August 2017
  • Author(s): Shreya Saxena, MBA

Request report

Related reports:
You may also be interested in: